Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, founded in 1886. The company operates through two segments: Innovative Medicine (pharmaceuticals, including the Janssen Biotech organization) and MedTech (medical devices). It researches, develops, manufactures, and supplies small‑molecule medicines and biologic therapies such as monoclonal antibodies, vaccines, and cell and gene therapies, alongside surgical, orthopedic, cardiovascular, and vision technologies. Following the 2023 separation of Kenvue, consumer health products are no longer part of Johnson & Johnson.
For the chemical and life‑sciences value chain, Johnson & Johnson maintains global GMP manufacturing and quality systems covering active pharmaceutical ingredients, biologics (including mammalian cell culture), sterile fill‑finish, and drug–device combination products. Its therapeutic focus spans oncology, immunology, neuroscience, infectious diseases, cardiovascular conditions, and pulmonary hypertension, among other areas. The company engages in collaborations and licensing with academic institutions and biotechnology firms in addition to internal R&D, supporting the progression of therapies from discovery through commercialization.
To provide comprehensive coverage, we aggregate data and news under the name J&J, encompassing the following company names, divisions, and related entities:
Janssen Biotech, Inc..
This list encompasses current and former names, alternate names, and key divisions associated with J&J, ensuring you can easily find all relevant information under a single, unified profile.